ineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The company is also developing technologies to increase the supply of donated lungs through ex-vivo perfusion of donor lungs prior to transplant. Sales and Distribution Distribution of Remodulin, Tyvaso and Orenitram: The company distributes Remodulin, Tyvaso and Orenitram throughout the United States and Puerto Rico through two contracted specialty pharmaceutical distributors: Accredo Health Group, Inc. (Accredo) and CVS Caremark (Caremark). These specialty pharmaceutical distributors are responsible for assisting patients with obtaining reimbursement for the cost of its treprostinil-based products and providing other support services. United States Distribution of Adcirca: The company sells Adcirca to pharmaceutical wholesalers. Under its manufacturing and supply agreement with Eli Lilly and Company (Lilly), Lilly manufactures Adcirca and distributes it via its wholesaler network, which includes Accredo and Caremark, in the same manner that it distributes its own pharmaceutical products. International Distribution of Remodulin: The company sells subcutaneous and intravenous Remodulin outside the United States to various distributors, each of which has exclusive distribution rights in one or more countries within Europe, Israel and the Middle East, Asia and South and Central America. The company also distributes Remodulin in Canada through a specialty pharmaceutical wholesaler. In some of the European markets where the company is not licensed to market Remodulin, such as Spain and the United Kingdom, the company sells Remodulin on a named-patient basis in which therapies are approved for individual patients by a national medical review board, hospital or health plan on a case-by-case basis. Research and Development The company’s research and development expenses, as of December 31, 2014, totaled approximately $242.5 million. Customers Accredo Health Group, Inc. accounted for 58 percent of the company’s revenues, as of December 31, 2014. History United Therapeutics Corporation was founded in 1996. The company was incorporated in Delaware in 1996.
united therapeutics corp (UTH:Frankfurt)
1040 Spring Street
Silver Spring, MD 20910
|Actelion Ltd||SFr.143.20 CHF||+1.40|
|Alexion Pharmaceuticals Inc||$182.24 USD||+4.44|
|Celanese Corp||$70.64 USD||-0.73|
|Nippon Shinyaku Co Ltd||¥5,320 JPY||+40.00|
|Vertex Pharmaceuticals Inc||$131.97 USD||-1.16|
|View Industry Companies|
Sponsored Financial Commentaries
To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.